04Recent Activity
Co-led R1 Therapeutics' $77.5M Series A with Abingworth and F-Prime Capital.
MAR 17, 2026
Participated in R1 Therapeutics' oversubscribed $77.5M Series A for hyperphosphatemia in CKD.
MAR 17, 2026
R1 Therapeutics is a clinical-stage biopharmaceutical company focusing on the development of first-in-class therapies for patients with kidney disease, particularly targeting hyperphosphatemia in chronic kidney disease patients on dialysis
R1 Therapeutics is a clinical-stage biopharmaceutical company focusing on the development of first-in-class therapies for patients with kidney disease, particularly targeting hyperphosphatemia in chronic kidney disease patients on dialysis.